Tag: MPH

Achievements, accolades highlight past year at VUMC | VUMC Reporter

  Editor’s note — the following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2023.   Whole-genome sequencing agreement Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center, and Illumina Inc., a global leader in DNA sequencing and array-based technologies,…

Continue Reading Achievements, accolades highlight past year at VUMC | VUMC Reporter

UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting

Faculty and trainees from the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) joined the world’s largest hematology community to discuss the latest updates in blood cancers at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held December 9-12, 2023 in San Diego and online. At the meeting,…

Continue Reading UChicago Medicine experts showcase blood cancer research at 65th ASH Annual Meeting

McLaren Reveals the Gorgeous GTS, a 626-HP Replacement for the GT

McLaren revealed a new model called the GTS, which is essentially a facelifted version of the GT. The GTS features the same twin-turbo 4.0-liter V-8, but now with 626 hp, a 14 hp bump. There are also new colors, wheels, and interior trim options. McLaren doesn’t usually deviate far from…

Continue Reading McLaren Reveals the Gorgeous GTS, a 626-HP Replacement for the GT

Karuna Therapeutics Inc. (KRTX) Reports Publication of Phase 3 EMERGENT-2 Trial Data on KarXT

Karuna Therapeutics, Inc. (NASDAQ: KRTX) today announced that results from the Phase 3 EMERGENT-2 trial of KarXT (xanomeline-trospium) in adults with schizophrenia were published in The Lancet. The manuscript shares KarXT data showcasing a clinically meaningful and statistically significant reduction in positive and negative symptoms of schizophrenia among adult patients…

Continue Reading Karuna Therapeutics Inc. (KRTX) Reports Publication of Phase 3 EMERGENT-2 Trial Data on KarXT

2024 Ford Mustang Trim Levels, Ranked By Engine Performance

The 2024 Ford Mustang is available in a multitude of different trims, each of which touts its own benefits. The EcoBoost Fastback provide excellent value for money, while the Dark Horse Mustang provides owners with the ultimate muscle car driving experience. HOTCARS VIDEO OF THE DAY SCROLL TO CONTINUE WITH…

Continue Reading 2024 Ford Mustang Trim Levels, Ranked By Engine Performance

Flooding, gusty winds forecast for Miami, Fort Lauderdale, Palm Beach. Secure holiday trim

The National Weather Service in Miami issued a flood watch Wednesday for large parts of South Florida while forecasters warned gusty winds plaguing the region over the next several days could blow away your holiday decorations. Flooding is possible in the coastal and metropolitan areas of Miami-Dade, Broward and Palm…

Continue Reading Flooding, gusty winds forecast for Miami, Fort Lauderdale, Palm Beach. Secure holiday trim

Flood watch issued for Miami, Fort Lauderdale and Palm Beach

Two men walk through a flood at West 14th Avenue and West 29 Street in Hialeah on Thursday, Nov. 16, 2023. Pedro Portal pportal@miamiherald.com The National Weather Service in Miami issued a flood watch Wednesday for large parts of South Florida while forecasters warned gusty winds could blow away your…

Continue Reading Flood watch issued for Miami, Fort Lauderdale and Palm Beach

Complete Interim Response, SCT Beats CAR T

Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…

Continue Reading Complete Interim Response, SCT Beats CAR T

Supreme Court Throws Out Cases On Covid Shot Mandates For Troops

The federal employee vaccine requirement was rescinded by President Joe Biden in May, and the Pentagon similarly withdrew a mandate for troops, but cases challenging the mandate for executive branch employees and military service members had rumbled on. CNN: Covid-19 Vaccine Mandates For Executive Branch Employees And Troops Thrown Out…

Continue Reading Supreme Court Throws Out Cases On Covid Shot Mandates For Troops

American Telemedicine Association announces new Clinician Council

© Jackie Niam – stock.adobe.com Physicians will help a national group guide American health care policy for virtual care. The American Telemedicine Association (ATA) announced a new Clinician Council “to address barriers to the broad adoption of telehealth and virtual care delivery, including emerging platforms that support technology-enabled health care.” The…

Continue Reading American Telemedicine Association announces new Clinician Council

2022 Hyundai Ioniq 5: Every Trim Compared

The Hyundai Ioniq 5 is the South Korean brand’s premier electric crossover, which launched the all-electric Ioniq portfolio in the U.S. The mid-size SUV in electric cars neatly balances futuristic aesthetics with contemporary design cues. It creates a unique-looking product that stays close to conventional car designs. TOPSPEED VIDEO OF…

Continue Reading 2022 Hyundai Ioniq 5: Every Trim Compared

Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T

Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…

Continue Reading Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T

Is Lifelong LDL-C Lowering Within Reach?

This transcript has been edited for clarity. Michelle L. O’Donoghue, MD, MPH: Hi. This is Dr Michelle O’Donoghue, reporting for Medscape. I’m here at the American Heart Association meeting, and one of the interesting stories that we’re going to be talking about is that of gene editing. Joining me to…

Continue Reading Is Lifelong LDL-C Lowering Within Reach?

How Does Tesla’s Ludicrous Mode Compare to Plaid?

The word “ludicrous” means so foolish, unreasonable, or out of place as to be amusing or ridiculous. Considering this definition, does it make sense that Elon Musk used this term to describe the high-performance mode of Tesla’s electric vehicles? Absolutely. The eccentric CEO gave us Ludicrous Mode and Ludicrous+ Mode…

Continue Reading How Does Tesla’s Ludicrous Mode Compare to Plaid?

Mini’s Electric Hot Hatch Is Finally Here in John Cooper Works Trim

Mini is fortifying its electrified lineup for 2025 and the Cooper SE JCW is its newest offering. With 215 hp and 243 lb-ft of torque, Mini has only confirmed the Cooper SE JCW for the European market. The electric hot hatch shows what the future of Mini’s JCW performance branch…

Continue Reading Mini’s Electric Hot Hatch Is Finally Here in John Cooper Works Trim

Ford Stole The “SS” Trim Level For One Car And It Was Super Slow: Glorious Garbage

You’re familiar with the term “early adopter,” right? The people who jump on something new as soon as possible, be it a piece of hardware, a type of software, or what have you. While hopping on the bandwagon early sometimes grants knowledge and status, it can also backfire because early…

Continue Reading Ford Stole The “SS” Trim Level For One Car And It Was Super Slow: Glorious Garbage

Last Large HIV Vaccine Trial Halted

PrEPVacc, the only current large HIV vaccine study, has been halted ahead of schedule because “there is little or no chance of the trial demonstrating vaccine efficacy in preventing HIV acquisition,” according to a December 6 announcement. Trial leaders shared the news at the International Conference on AIDS and STIs…

Continue Reading Last Large HIV Vaccine Trial Halted

Electric 2025 Mini Cooper SE Gets John Cooper Works Looks, But No Added Grunt

The JCW Trim version of the Cooper SE retains the standard model’s 215 hp electric motor and has the same 250 miles of range www.carscoops.com/author/bradcarscoops-com/ by Brad Anderson 6 hours ago We have good news for those who want to pick up the keys to the new Mini Cooper S,…

Continue Reading Electric 2025 Mini Cooper SE Gets John Cooper Works Looks, But No Added Grunt

Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial

PARSIPPANY, N.J. & SAN DIEGO–(BUSINESS WIRE)– Melinta Therapeutics, LLC and Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced the peer-reviewed publication of pooled data from two completed global clinical trials evaluating REZZAYO® (rezafungin for injection) for the treatment of candidemia and invasive candidiasis. The article, “Efficacy and safety of rezafungin and…

Continue Reading Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial

FDA Launches Priority Review of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer

FDA Launches Priority Review of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer The supplemental biologics license application (sBLA) for enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) has received priority review from the FDA. The combination is being considered as frontline treatment for patients with locally advanced or metastatic urothelial cancer. The…

Continue Reading FDA Launches Priority Review of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer

We Finally Know How Much The Cybertruck Actually Costs, Here’s The Price Of Every Trim

The difference between the current least expensive and most expensive Cybertruck trims is $39,000 — and more so if you factor in the $7,500 tax credit that comes with the former. However, that higher price might be worth it to you if you’re looking for more speed, power, and range….

Continue Reading We Finally Know How Much The Cybertruck Actually Costs, Here’s The Price Of Every Trim

FDA Grants Priority Review for Pembrolizumab Combo in Bladder Cancer

Supporting data for the sBLA came from the phase 3 EV-302/KEYNOTE-A39 trial (NCT04223856), in which the pembrolizumab combination significantly extended the primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with locally advanced or metastatic urothelial cancercompared withstandard platinum-containing chemotherapy. The FDA has given priority review to…

Continue Reading FDA Grants Priority Review for Pembrolizumab Combo in Bladder Cancer

Tesla Announces Final Cybertruck Specs and Pricing Across Trim Levels

November 30, 2023 By Not a Tesla App Staff Tesla just finished its Cybertruck delivery event and has now announced final specs and pricing for its three Cybertruck variants. Specifications and Prices RWD Cybertruck Estimated Price: $60,990 Availability: 2025 Estimated Range: 250 miles Acceleration: 0-60 mph in 6.5 seconds AWD…

Continue Reading Tesla Announces Final Cybertruck Specs and Pricing Across Trim Levels

2024 Tesla Cybertruck Has 845-HP Cyberbeast Trim, Baseball-Deflecting Body

No, your eyes are not deceiving you. The Tesla Cybertruck is finally here. The production-spec electric pickup was revealed at an event at Tesla’s Gigafactory in Austin, Texas, that was livestreamed on X, formerly known as Twitter. CEO Elon Musk started off the event by proclaiming, “You have a car…

Continue Reading 2024 Tesla Cybertruck Has 845-HP Cyberbeast Trim, Baseball-Deflecting Body

Tesla Cybertrucks deliveries begin, lowest trim US$61,000

Breadcrumb Trail Links Preview Pickup trucks New Vehicles Electric Vehicles Turns out a “Cyberbeast” trim will apparently offer more than 700 km on a charge thanks to a range extender Published Nov 30, 2023  •  Last updated 1 day ago  •  4 minute read The Tesla Cybertruck on display at the…

Continue Reading Tesla Cybertrucks deliveries begin, lowest trim US$61,000

price, range, trims, and specs revealed

Tesla has finally revealed the pricing, range, trims, and other specifications of the Cybertruck at its delivery event at Gigafactory Texas today, as it handed over the first units to customers on Thursday afternoon. After four years, Tesla finally made the first deliveries of the Cybertruck in what will be…

Continue Reading price, range, trims, and specs revealed

MIL-OSI USA: Whole Genome Sequencing: Cracking the Genetic Code for Foodborne Illness

Recommended Sponsor Painted-Moon.com – Buy Original Artwork Directly from the Artist Source: US Food and Drug Administration-1 A person commits a crime, and the detective uses DNA evidence collected from the crime scene to track the criminal down. An outbreak of foodborne illness makes people sick, and the U.S. Food…

Continue Reading MIL-OSI USA: Whole Genome Sequencing: Cracking the Genetic Code for Foodborne Illness

MEDICURE ANNOUNCES FDA PROVIDES COMPLETE APPROVAL TO ENROLL PATIENTS IN ITS PIVOTAL PHASE 3 TRIAL FOR TREATMENT OF RARE PEDIATRIC DISEASE -November 24, 2023 at 07:29 am EST

CANADA – Medicure Inc. (‘Medicure‘ or the ‘Company’) (TSXV: MPH, OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3…

Continue Reading MEDICURE ANNOUNCES FDA PROVIDES COMPLETE APPROVAL TO ENROLL PATIENTS IN ITS PIVOTAL PHASE 3 TRIAL FOR TREATMENT OF RARE PEDIATRIC DISEASE -November 24, 2023 at 07:29 am EST

Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

WINNIPEG, MB / ACCESSWIRE / November 23, 2023 / Medicure Inc. (‘Medicure‘ or the ‘Company‘) (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that the FDA provides complete approval to enroll patients…

Continue Reading Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics

Quotient’s Somatic Genomics platform reveals new approaches to treat disease based on the vast genetic variation present in the body’s trillions of cells Company emerges from stealth after two years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., Nov. 21, 2023 /PRNewswire/ —…

Continue Reading Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics

Key Efficacy and Tolerability Factors for Later-Line Therapies in RCC

Arnab Basu, MD, MPH Assistant Professor UAB Medicine Birmingham, AB DISCUSSION QUESTIONS From the TIVO-3 (NCT02627963) data set, what efficacy parameters appeal about tivozanib (Fotivda)? What role is there for sustained VEGF inhibition in the relapsed/refractory renal cell carcinoma (RCC) setting? ARNAB BASU, MD, MPH: From all the data that…

Continue Reading Key Efficacy and Tolerability Factors for Later-Line Therapies in RCC

Phase 3 DUO-E Study Findings Prove ‘Exciting’ in Advanced Endometrial Cancer

Findings from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial (NCT04269200)—assessing combination chemotherapy/durvalumab (Imfinzi), single-agent durvalumab, and durvalumab/olaparib (Lynparza) in patients with newly diagnosed advanced or recurrent endometrial cancer—were “exciting,” according to Shannon N. Westin, MD, MPH, FACOG. In a conversation with CancerNetwork® during the 2023 Annual Global Meeting of the International Gynecologic…

Continue Reading Phase 3 DUO-E Study Findings Prove ‘Exciting’ in Advanced Endometrial Cancer

Student research celebrated at Health Sciences Research Day

MU School of Medicine students presented roughly 250 research projects at the annual 2023 Health Sciences Research Day (HSRD), held Nov. 10, 2023, and featured the work of undergraduates, medical and nursing students, PhD students and postdoctoral trainees. The research posters covered a variety of topics within the health care…

Continue Reading Student research celebrated at Health Sciences Research Day

The effects of methylphenidate and atomoxetine on Drosophila brain at single-cell resolution and potential drug repurposing for ADHD treatment

Both MPH and ATX increase the locomotor activity of wild-type Drosophila To investigate the cell type-specific molecular mechanisms of ADHD drugs in the brain at single-cell resolution, we conducted behavioral experiments and scRNASEQ in wild-type (WT) adult male Drosophila melanogaster following exposure to MPH, ATX, and control treatment. Here, we…

Continue Reading The effects of methylphenidate and atomoxetine on Drosophila brain at single-cell resolution and potential drug repurposing for ADHD treatment

Personalized Treatment Sequencing Is a New Way of Thinking in Breast Cancer

Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancers, senior physician at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, all in Boston, Massachusett In a rapidly evolving field, new strides…

Continue Reading Personalized Treatment Sequencing Is a New Way of Thinking in Breast Cancer

The right measurement frameworks matter for demonstrating treatment efficacy in clinical trials for Alzheimer’s Disease

Alzheimer’s disease is more than a neurodegenerative disorder. For the 6 million people living with the disease1 (and their caregivers), mild, moderate or severe symptoms are the cause of lost memories, forgotten faces, declines in reasoning and poor decision-making.2 Since 2021, pivotal trials that demonstrated some clinical benefit led to…

Continue Reading The right measurement frameworks matter for demonstrating treatment efficacy in clinical trials for Alzheimer’s Disease

Karina Ascunce, Editor at Simply Psychology

Highlights Karina Ascunce González graduated from Harvard University in May 2022 with an A.B. in Neuroscience and a secondary in Global Health & Health Policy Karina is currently a PhD Student in Biological and Biomedical Sciences, Neuroscience Track at Yale University. In addition to her PhD research, Karina is conducting…

Continue Reading Karina Ascunce, Editor at Simply Psychology

Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant | Cardiology | JAMA Cardiology

Key Points Question  Is clonal hematopoiesis of indeterminate potential (CHIP) detected at the time of hematopoietic stem transplant (HCT) associated with increased rates of cardiovascular disease (CVD) among patients with multiple myeloma (MM) following HCT? Finding  In this cohort study of patients with MM undergoing HCT, CHIP was highly prevalent…

Continue Reading Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant | Cardiology | JAMA Cardiology

VistaGen Therapeutics (VTGN) to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the Company will present at two upcoming scientific conferences in November. “Vistagen’s presentations highlight the significant progress we have made to…

Continue Reading VistaGen Therapeutics (VTGN) to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences

Long-Term Treatment With Dupixent Safe, Effective in Children With EoE

In the first analysis of longer-term data in children aged 1 to 11 years with eosinophilic esophagitis (EoE), a higher dose of Dupixent (dupilumab) was shown safe and effective for up to one year in a phase 3 trial. The results were presented at the American College of Gastroenterology 2023…

Continue Reading Long-Term Treatment With Dupixent Safe, Effective in Children With EoE

Novel Therapies Have Significantly Improved Melanoma Outcomes, With More Exciting Options to Come

For a long time, surgery was the only real treatment option available for melanoma, but there are new therapies that have significantly improved outcomes, at a cost. During an Institute for Value-Based Medicine event in Minneapolis, Minnesota, cohosted by The American Journal of Managed Care and Minnesota Oncology, a group…

Continue Reading Novel Therapies Have Significantly Improved Melanoma Outcomes, With More Exciting Options to Come

Adding a Specimen Type to PCR Testing Demonstrates an Increase in RSV Diagnosis

In hospitalized adult patients, RSV diagnosis is typically assessed on PCR testing using nasopharyngeal (NP) swabs. This can be problematic for 2 reasons explains Elizabeth Begier, MD, MPH, senior director, scientific affairs lead, RSV Antiviral/Adult Vaccine Program, Pfizer Vaccines. “The two primary challenges are first that RSV is actually infrequently…

Continue Reading Adding a Specimen Type to PCR Testing Demonstrates an Increase in RSV Diagnosis

Using AI to Optimize Therapeutic Choices and QOL in Patients With Cancer

In an interview with Peers and Perspectives in Oncology, Tim Showalter, MD, MPH, vice president of clinical development at ArteraAI and professor in the Radiation Oncology Department at the University of Virginia School of Medicine, discussed increasing patient quality of life (QOL) by using artificial intelligence (AI) and precision medicine…

Continue Reading Using AI to Optimize Therapeutic Choices and QOL in Patients With Cancer

Combined Therapeutics to Present at 11th International mRNA Health Conference | DNA RNA and Cells

Combined Therapeutics to Present at 11th International mRNA Health Conference Details Category: DNA RNA and Cells Published on Thursday, 26 October 2023 11:46 Hits: 620 Dr. Romain Micol, President and Chief Executive Officer, will provide an update on Combined Therapeutics’ proprietary MOPCTx mRNA platform, which controls where the protein is…

Continue Reading Combined Therapeutics to Present at 11th International mRNA Health Conference | DNA RNA and Cells

Moderna (MRNA) and Caris Life Sciences Enter Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics

Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced a new agreement with Moderna (NASDAQ: MRNA) in support of Moderna’s oncology and novel…

Continue Reading Moderna (MRNA) and Caris Life Sciences Enter Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics

Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics

Partnership enables Moderna to leverage Caris’ vast library of de-identified, multi-modal data and analytics capabilities to accelerate precision medicine and the delivery of novel medicines to patients IRVING, Texas, Oct. 24, 2023 /PRNewswire/ — Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively…

Continue Reading Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics

Tropical Parasite May Be Endemic in Texas

A parasitic disease that can cause skin ulcers and is usually spread by the tiny sandfly may now be endemic to the U.S., preliminary findings from CDC researchers suggested. Genetic sequencing of 2,235 U.S. cutaneous leishmaniasis samples submitted from 2005 to 2019 confirmed the presence of a potentially distinct genotype…

Continue Reading Tropical Parasite May Be Endemic in Texas

Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer

Shannon N. Westin, MD, MPH, FACOG The addition of durvalumab (Imfinzi) to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib (Lynparza) significantly improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial (NCT04269200) presented at…

Continue Reading Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer

Durvalumab/Olaparib Maintenance Induces PFS Benefit in Advanced, Recurrent Endometrial Cancer

The addition of durvalumab (Imfinzi) to first-line chemotherapy, followed by maintenance therapy with the anti-PD-L1 antibody plus olaparib (Lynparza) improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial (NCT04269200) presented at ESMO Congress 2023.1-3 In particular,…

Continue Reading Durvalumab/Olaparib Maintenance Induces PFS Benefit in Advanced, Recurrent Endometrial Cancer

Blood-Based Testing for Multicancer Early Detection

By Matthew StengerPosted: 10/19/2023 12:17:00 PM Last Updated: 10/19/2023 1:59:52 PM In a prospective cohort study (PATHFINDER) reported in The Lancet, Deb Schrag, MD, MPH, FASCO, and colleagues evaluated the performance of blood-based testing for multicancer early detection in adults without signs or symptoms of cancer.  As stated by the…

Continue Reading Blood-Based Testing for Multicancer Early Detection

Phase 3 data support nemolizumab for atopic dermatitis, prurigo nodularis treatment

October 19, 2023 1 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

Continue Reading Phase 3 data support nemolizumab for atopic dermatitis, prurigo nodularis treatment

Bringing equity to genomic sequencing in newborns

Credit: Unsplash/CC0 Public Domain Today, nearly 900 disorders caused by a single gene are known to be treatable. Yet the recommended “heel stick” testing for newborns only covers about 60 inherited, treatable disorders, and many individual states screen for fewer. What if newborns could instead have their entire genome sequenced…

Continue Reading Bringing equity to genomic sequencing in newborns

Lung, kidney, and neuroendocrine tumor cancer

BOSTON – Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain. The studies will be presented both in-person and online on October 20-24, 2023. A…

Continue Reading Lung, kidney, and neuroendocrine tumor cancer

Latest Phase 3 Trial Data Announced for Upadacitinib Treatment of Atopic Dermatitis

Jonathan Silverberg, MD Credit: gwdocs.com The drug upadacitinib may be safe and effective long-term in treating patients with moderate-to-severe atopic dermatitis (AD) across 140 weeks, according to new data presented at the 32nd European Academy of Dermatology and Venereology (EADV) Congress in Berlin.1 These findings, announced by AbbVie from EADV,…

Continue Reading Latest Phase 3 Trial Data Announced for Upadacitinib Treatment of Atopic Dermatitis

Zanubrutinib Plus Obinutuzumab Approaches EU Approval in R/R Follicular Lymphoma

Mehrdad Mobasher, MD, MPH The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of zanubrutinib (Brukinsa) in combination with obinutuzumab (Gazyva) for use in adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 lines of systemic treatment.1…

Continue Reading Zanubrutinib Plus Obinutuzumab Approaches EU Approval in R/R Follicular Lymphoma

When to treat DLBCL with radiotherapy?

SAN DIEGO – Radiation has become a crucial component of treatment for diffuse large B cell lymphoma (DLBCL) over the past 25 years. But radiologists presenting at an annual conference cautioned colleagues to keep the limitations of radiology in mind and not to assume that it’s always a necessary adjunct…

Continue Reading When to treat DLBCL with radiotherapy?

Positive Phase 3 Results Announced for Nemolizumab Treatment of Atopic Dermatitis, Prurigo Nodularis

Nemolizumab may lead to substantial improvements for those with prurigo nodularis (PN) and atopic dermatitis (AD), according to new phase 3 data presented at the 2023 European Academy of Dermatology and Venereology (EADV) congress in Berlin.1 These findings were announced by Galderma, with 3 studies yielding positive results for both…

Continue Reading Positive Phase 3 Results Announced for Nemolizumab Treatment of Atopic Dermatitis, Prurigo Nodularis

DELFI Diagnostics to Highlight Breakthrough Technology and Completed Clinical Study in Lung Cancer Detection

DELFI leadership to announce advancement with whole-genome machine learning for lung cancer detection test at HLTH 2023; Presentation of DELFI’s L101 clinical validation study at CHEST Annual Meeting BALTIMORE and PALO ALTO, Calif., Oct. 4, 2023 /PRNewswire/ — DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a…

Continue Reading DELFI Diagnostics to Highlight Breakthrough Technology and Completed Clinical Study in Lung Cancer Detection

BabySeq 2 aims to bring equity to newborn genomic sequencing

The groundbreaking BabySeq study has a new initiative: making genomic sequencing accessible to a more diverse population of newborns. (Images: AdobeStock, Illustration: Sebastian Stankiewicz, Boston Children’s Hospital) Today, nearly 900 disorders caused by a single gene are known to be treatable. Yet the recommended “heel stick” testing for newborns only…

Continue Reading BabySeq 2 aims to bring equity to newborn genomic sequencing

Genomic epidemiology reveals multidrug resistant plasmid spread between Vibrio cholerae lineages in Yemen

V. cholerae in Yemen in 2018 and 2019 The National Centre of Public Health Laboratories (NCPHL) in Sana’a, the capital city of Yemen, received 6,311 and 3,225 clinical samples from suspected cholera patients in 2018 and 2019, respectively (Supplementary Table 1). Of these, 2,204 (35%) and 2,171 (67%) were confirmed…

Continue Reading Genomic epidemiology reveals multidrug resistant plasmid spread between Vibrio cholerae lineages in Yemen

CNM-Au8 Shows Significant Long-Term Survival Improvement in HEALEY ALS Platform Trial

Newly announced long-term follow-up data from Regimen C of the HEALEY ALS platform trial (NCT04297683) assessing the investigational agent CNM-Au8 (Clene Nanomedicine) in patients with amyotrophic lateral sclerosis (ALS) showed a decreased risk of mortality for up to 133 weeks in treated patients compared with placebo-treated patients from the Pooled…

Continue Reading CNM-Au8 Shows Significant Long-Term Survival Improvement in HEALEY ALS Platform Trial

Sborov and Participants Discuss Later-Line Treatment in Multiple Myeloma

Douglas W. Sborov, MD, MS (MODERATOR) Associate Professor, Division of Hematology and Hematologic Malignancies Department of Internal Medicine University of Utah School of Medicine Huntsman Cancer Institute Salt Lake City, UT EVENT REGION Arizona, Colorado, New Mexico, Utah PARTICIPANT LIST Christopher Chen, MD | Muhammad Anas Tarajki, MD | Darshil…

Continue Reading Sborov and Participants Discuss Later-Line Treatment in Multiple Myeloma

Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up

Arcutissubmits roflumilast 0.15% sNDAfor AD in children 6 years and up | Image Credit: © lial88 – © lial88 – stock.adobe.com. A supplemental New Drug Application (sNDA) has been submitted to the FDA by Arcutis Biotherapeutics for roflumilast cream 0.15%, a steroid-free, once-daily topical to treat mild to moderate atopic…

Continue Reading Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up

Postdoctoral Associate in Bioinformatics job with University of Florida

Postdoctoral Associate in Bioinformatics Job No: 528604Work Type: Post Doc AssociateLocation: Main Campus (Gainesville, FL)Categories: Grant or Research Administration, Health Care Administration/Support, Physical/Mathematical SciencesDepartment: 36010000 – PHHP-COM BIOSTATISTICS Job Description Classification Title: Postdoctoral Associate Job Description: Dr. Li Chen’s laboratory (lichen-lab.github.io/) at the University of Florida’s Department of Biostatistics (biostat.ufl.edu/)…

Continue Reading Postdoctoral Associate in Bioinformatics job with University of Florida

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Topline data from Phase 3 trial expected in Q4 2024 Company to present encore 36-month efficacy, safety, and patient-reported outcomes data from the Phase 2 TOPAZ trial extension at the 2023 World Muscle Society (WMS) Annual Congress Apitegromab is the only muscle-targeted therapy candidate with clinical data showing proof of…

Continue Reading Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Arcutis Announces Successful Phase 3 Results for Roflumilast Cream 0.05% in Children with Atopic Dermatitis

Biopharmaceutical company Arcutis Biotherapeutics announced the successful achievement of the primary and secondary endpoints of the INTEGUMENT-PED phase 3 study on roflumilast cream 0.05% for those in the age range of 2 to 5 years with mild-to-moderate atopic dermatitis (AD).1 Roflumilast cream 0.05% is a steroid-free topical cream that is…

Continue Reading Arcutis Announces Successful Phase 3 Results for Roflumilast Cream 0.05% in Children with Atopic Dermatitis

Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs

Apnimed, Inc. – Seasoned biopharma medical leader joins Apnimed as it initiates its Phase 3 clinical program for AD109, a potential new oral treatment for Obstructive Sleep Apnea John Yee, MD, MPH John Yee, MD, MPH, Senior Vice President of Medical Affairs, Apnimed CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE)…

Continue Reading Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs

Rapid DNA Sequencing Yields Timely Answers for Infant Epilepsy – Be part of the knowledge

Rapid GS workflow and summary of genetic diagnoses. (A) Rapid GS workflow and time intervals, created with BioRender.com. (B) Genetic diagnoses arranged by age at seizure onset. Each square represents an infant who received a genetic diagnosis. The affected gene or genomic region is denoted in the square. The infant…

Continue Reading Rapid DNA Sequencing Yields Timely Answers for Infant Epilepsy – Be part of the knowledge

Updated COVID-19 Vaccines; National Blood Shortages; Lack of Doctor Diversity

FDA Approves Updated COVID-19 Vaccines On Monday, the FDA approved 2 updated COVID-19 booster vaccines for people as young as 6 months, according to STAT. This may result in Moderna and Pfizer-BioNTech vaccines becoming available in doctors’ offices, clinics, and pharmacies later in the week. The Advisory Committee on Immunization…

Continue Reading Updated COVID-19 Vaccines; National Blood Shortages; Lack of Doctor Diversity

Rapid DNA sequencing yields timely answers for infant epilepsy

Rapid GS workflow and summary of genetic diagnoses. (A) Rapid GS workflow and time intervals, created with BioRender.com. (B) Genetic diagnoses arranged by age at seizure onset. Each square represents an infant who received a genetic diagnosis. The affected gene or genomic region is denoted in the square. The infant…

Continue Reading Rapid DNA sequencing yields timely answers for infant epilepsy

Should you buy a walking pad?

This is an installment of Good Fit, a column about exercise. Though Antonella Avogadro’s job as a software engineer normally ties her to her desk for most of the day, she still manages to get in about 10,000 steps—and sometimes even up to 20,000 steps—before clocking out. On the days she…

Continue Reading Should you buy a walking pad?

Retrospective Data Show Aggressive Axillary Surgery Is Not Associated With Improved Outcomes in Select Patients With Breast Cancer

Raymond Mailhot Vega, MD, MPH More aggressive axillary surgery was not associated with improved outcomes in patients with cN1 breast cancer that became ycN0 but remained node positive following neoadjuvant chemotherapy, according to findings from a retrospective analysis of patients treated in the phase 3 NSABP B-40 (NCT00408408) and NSABP…

Continue Reading Retrospective Data Show Aggressive Axillary Surgery Is Not Associated With Improved Outcomes in Select Patients With Breast Cancer

CDC Details Multidrug-Resistant TB Outbreak in an Unlikely Spot

An outbreak of multidrug-resistant tuberculosis (TB) developed in Kansas in November 2021, and included multiple children who were born in the U.S. and became infected in the state, CDC researchers reported. The outbreak involved 13 people across four households in Kansas City and spanned 1 year. While a majority of…

Continue Reading CDC Details Multidrug-Resistant TB Outbreak in an Unlikely Spot

Emergence of ST248Pasteur-ST1068Oxford | IDR

Acinetobacter pittii is a crucial pathogen that mainly causes healthcare-associated infections, including pneumonia, bloodstream infections (BSIs) and urinary tract infections (UTIs).1 Carbapenem-resistant A. pittii (CRAP) poses a huge challenge in clinical settings. CRAP is increasingly recognized as a significant pathogen of hospital-acquired infections in the hospital.2 Carbapenem resistance in A….

Continue Reading Emergence of ST248Pasteur-ST1068Oxford | IDR

Cabozantinib Efficacy Prompts CABINET Trial Unblinding in Advanced Pancreatic and Extra-Pancreatic NETs

Interim data from the phase 3 CABINET trial (NCT03375320) demonstrated significant improvement in progression-free survival (PFS) with cabozantinib (Cabometyx) vs placebo in patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors (NETs) following progression on prior systemic therapy. As such, the trial will be unblinded and discontinued following a unanimous decision…

Continue Reading Cabozantinib Efficacy Prompts CABINET Trial Unblinding in Advanced Pancreatic and Extra-Pancreatic NETs

High-Risk MDS Patients May Benefit from Allogenic Transplants

Study Title: Allogeneic Hematopoietic Cell Transplantation Improves Outcome in MDS across High-Risk genetic subgroups: Genetic analysis of the BMT CTN 1102 study Publication: Journal of Clinical Oncology, Click here for link Dana-Farber Authors: Jurjen Versluis, MD; Christopher J. Gibson, MD; Corey Cutler, MD, MPH, FRCPC; R. Coleman Lindsley, MD, PhD…

Continue Reading High-Risk MDS Patients May Benefit from Allogenic Transplants

Assessing Factors for Sequencing Therapies in ER+ Advanced Breast Cancer

CASE SUMMARY A 62-year-old woman presented with a 6 cm right breast mass, which has been slowly growing for 1 year with palpable axillary nodes​. Her liver function test was within normal limits and a CT scan showed 2 liver nodules, with the largest being 2 cm​. A bone scan showed…

Continue Reading Assessing Factors for Sequencing Therapies in ER+ Advanced Breast Cancer

Assistant Professor (Tenure Track) in Epidemiology job with University Of Maryland, College Park

The Department of Epidemiology and Biostatistics, at The University of Maryland School of Public Health, College Park (www.sph.umd.edu/EPIB) invites applications for a tenure-track Assistant Professor position in Epidemiology.    The Department’s mission is to improve health and reduce health disparities in local communities, the state of Maryland, and the nation….

Continue Reading Assistant Professor (Tenure Track) in Epidemiology job with University Of Maryland, College Park

Tofu the Culprit in Canadian Salmonella Outbreak

A recent outbreak of Salmonella Typhimurium infections in Ontario, Canada had an unprecedented link to a plant-based protein, researchers found. From May to mid-August of 2021, public health and food safety authorities investigated a cluster of 38 patients across multiple public health districts in Ontario; five patients were hospitalized, though…

Continue Reading Tofu the Culprit in Canadian Salmonella Outbreak

Evaluating the Role of Loncastuximab in Relapsed/Refractory DLBCL

Brad Haverkos, MD, MPH, MS Associate Professor, Medicine-Hematology University of Colorado School of Medicine Aurora, CO DISCUSSION QUESTIONS How has the approval of loncastuximab tesirine (Zynlonta) addressed an unmet need in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)? ​ In which patient population is loncastuximab most suitable for? ​ Are there any instances…

Continue Reading Evaluating the Role of Loncastuximab in Relapsed/Refractory DLBCL

Method for Depletion of Mitochondria DNA in Human Bronchial Epithelial Cells

Introduction: Mitochondria are increasingly recognized to play a role in the airway inflammation of asthma. Model systems to study the role of mitochondrial gene expression in bronchial epithelium are lacking. Here, we create custom bronchial epithelial cell lines derived from primary airway epithelium that are depleted of mitochondrial DNA. Methods:…

Continue Reading Method for Depletion of Mitochondria DNA in Human Bronchial Epithelial Cells

Zipalertinib Plus Chemotherapy Moves to Phase 3 Study in EGFR Exon 20 Insertion+ NSCLC

The safety and efficacy of zipalertinib (CLN-081, TAS6417) plus platinum-based chemotherapy will be compared with platinum-based chemotherapy alone in patients with treatment-naïve, locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations in the phase 3 REZILIENT3 trial (NCT05973773).1 Previously, results from a phase 1/2a…

Continue Reading Zipalertinib Plus Chemotherapy Moves to Phase 3 Study in EGFR Exon 20 Insertion+ NSCLC

Investigators Launch Phase 3 Zipalertinib Combo Trial in EGFR+ NSCLC

Developers designed the orally available small molecule zipalertinib as an irreversible EGFR inhibitor for treating a genetically defined group of patients with NSCLC. Developers have initiated the phase 3 REZILIENT3 trial (NCT05973773) to assess zipalertinib (CLN-081/TAS6417) plus chemotherapy as a frontline treatment option for adult patients with EGFR exon 20…

Continue Reading Investigators Launch Phase 3 Zipalertinib Combo Trial in EGFR+ NSCLC

Elevar Therapeutics to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib in Combination with Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)

Elevar Therapeutics FORT LEE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced it will host a virtual…

Continue Reading Elevar Therapeutics to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib in Combination with Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)

CDC Committee Votes Unanimously to Recommend Nirsevimab for Preventing RSV in Infants

The CDC’s ACIP voted today to recommend nirsevimab-alip (Beyfortus) for the protection against severe respiratory syncytial virus (RSV) in the first respiratory virus season for all infants and for a second season for those who remain at increased risk for severe RSV. Specifically, the ACIP committee voted on the following…

Continue Reading CDC Committee Votes Unanimously to Recommend Nirsevimab for Preventing RSV in Infants

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023

ROCKVILLE, Md.–(BUSINESS WIRE)– GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the second quarter ended June 30, 2023. Cash and cash equivalents as of June 30, 2023 were $58.0 million. “With the…

Continue Reading GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023

Considerations for Third-Line Therapy for Relapsed/Refractory DLBCL

Brad Haverkos, MD, MPH, MS Associate Professor, Medicine-Hematology University of Colorado School of Medicine Aurora, CO CASE SUMMARY: A 73-year-old woman presented with fever, headaches, and 7-lb unintentional weight loss​. She is married with 2 grown children who live in other states; she is the primary caretaker for her mother who…

Continue Reading Considerations for Third-Line Therapy for Relapsed/Refractory DLBCL

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical…

Continue Reading Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Formula E car hits 218km/h indoors to smash Guiness World Record

The official GUINNESS WORLD RECORDS title was achieved by driver Jake Hughes of NEOM McLaren Formula E Team who competed with ABB FIA Formula E World Championship rival, Mahindra Racing team driver Lucas di Grassi, to set the world record for the fastest speed achieved by a vehicle indoors. The…

Continue Reading Formula E car hits 218km/h indoors to smash Guiness World Record

Weekly Insulin Shot Could Be a Game Changer for Those With Type 2 Diabetes

By Dennis Thompson HealthDay Reporter TUESDAY, July 18, 2023 People with type 2 diabetes could soon have access to convenient once-a-week insulin shots that could replace the daily injections now required. A once-weekly insulin formulation called icodec performed just as well as daily doses of the insulin degludec, phase 3…

Continue Reading Weekly Insulin Shot Could Be a Game Changer for Those With Type 2 Diabetes

Breast Cancer Research Breakthroughs Signal Paradigm Shifts Across Disease Subsets

Continued research efforts have solidified the use of targeted therapies in hormone receptor (HR)–positive breast cancer and indicate the importance of further research with novel agents, such as HER3-directed antibody-drug conjugates (ADCs) in metastatic disease, according to Maryam Lustberg, MD, MPH. Among breast cancer data presented at the 2023 ASCO…

Continue Reading Breast Cancer Research Breakthroughs Signal Paradigm Shifts Across Disease Subsets

In New Era of Gene Therapy, PCPs Are ‘Boots on the Ground’

In Colorado and Wyoming, nearly every baby born since 2020 is tested for signs of a mutation in the SMN1 gene, an indicator of spinal muscular atrophy (SMA). And in 4 years, genetic counselor Melissa Gibbons has seen 24 positive results. She has prepped 24 different pediatricians and family doctors…

Continue Reading In New Era of Gene Therapy, PCPs Are ‘Boots on the Ground’

Whole Genome Sequencing Takes the Lead in Unraveling Genetic Disorders

The study, “A Comparative Analysis of Rapid Whole Genomic Sequencing and a Targeted Neonatal Gene Panel in Infants with a Suspected Genetic Disorder: The Genomic Medicine for Ill Neonates and Infants (GEMINI) Study,” was first published online in ). Funded by the National Institutes of Health, the first-of-its-kind GEMINI Study…

Continue Reading Whole Genome Sequencing Takes the Lead in Unraveling Genetic Disorders

FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

The FDA has accepted a supplemental biologics license application (sBLA) seeking the approval of zanubrutinib (Brukinsa) in combination with obinutuzumab (Gazyva) in the treatment of adult patients with relapsed/refractory follicular lymphoma who received at least 2 prior lines of therapy.1 The sBLA is supported by data from the phase 2…

Continue Reading FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

Genome Sequencing Nearly Twice as Effective as Targeted Gene-Sequencing in Newborns and Infants

A new national study, led by researchers at Tufts Medical Center in Boston, has found whole genome sequencing (WGS) to be nearly twice as effective as a targeted gene sequencing test at identifying abnormalities responsible for genetic disorders in newborns and infants. The study, “A Comparative Analysis of Rapid Whole…

Continue Reading Genome Sequencing Nearly Twice as Effective as Targeted Gene-Sequencing in Newborns and Infants

Genome sequencing highly effective at diagnosing genetic disorders in newborns and infants — ScienceDaily

A new national study, led by researchers at Tufts Medical Center in Boston, has found whole genome sequencing (WGS) to be nearly twice as effective as a targeted gene sequencing test at identifying abnormalities responsible for genetic disorders in newborns and infants. The study, “A Comparative Analysis of Rapid Whole…

Continue Reading Genome sequencing highly effective at diagnosing genetic disorders in newborns and infants — ScienceDaily

Whole genome sequencing shows promise for early diagnosis of genetic disorders in newborns, infants

A new national study, led by researchers at Tufts Medical Center in Boston, has found whole genome sequencing (WGS) to be nearly twice as effective as a targeted gene sequencing test at identifying abnormalities responsible for genetic disorders in newborns and infants. The study, “A Comparative Analysis of Rapid Whole…

Continue Reading Whole genome sequencing shows promise for early diagnosis of genetic disorders in newborns, infants

Genome Sequencing Outperforms Targeted Gene-Sequencing Test in Diagnosing Genetic Disorders in Newborns

July 11, 2023 (BOSTON) – A new national study, led by researchers at Tufts Medical Center in Boston, has found whole genome sequencing (WGS) to be nearly twice as effective as a targeted gene sequencing test at identifying abnormalities responsible for genetic disorders in newborns and infants. The study, “A…

Continue Reading Genome Sequencing Outperforms Targeted Gene-Sequencing Test in Diagnosing Genetic Disorders in Newborns

Whole Genome Sequencing Boosts Diagnosis of Rare Disease in Infants

Whole genome sequencing captured almost twice as many genetic abnormalities that may be responsible for disease in infants, compared with a standard targeted test, researchers found. In the Genomic Medicine for Ill Neonates and Infants (GEMINI) study, the diagnostic yield of whole genome sequencing was 49%, compared with 27% with…

Continue Reading Whole Genome Sequencing Boosts Diagnosis of Rare Disease in Infants

WGS More Effective than Targeted Gene Sequencing For Diagnosing Genetic Diseases in Newborns

A national study, led by researchers at Tufts Medical Center, has found whole genome sequencing (WGS) to be nearly twice as effective as a targeted gene sequencing test at identifying abnormalities responsible for genetic disorders in newborns and infants. The Genomic Medicine in Ill Infants and Newborns (GEMINI) study did,…

Continue Reading WGS More Effective than Targeted Gene Sequencing For Diagnosing Genetic Diseases in Newborns